

BIOINFORMANT

Global Cord Blood and Tissue Banking Industry Report



**1ST AND ONLY MARKET RESEARCH FIRM TO
SPECIALIZE IN THE STEM CELL INDUSTRY**

TABLE OF CONTENTS

1.	REPORT OVERVIEW.....	15
1.1	Statement of the Report.....	16
1.2	Executive Summary.....	17
1.3	Introduction.....	20
2.	CORD BLOOD & CORD BLOOD BANKS: AN OVERVIEW.....	22
2.1	Composition of a Cord Blood Sample.....	24
2.2	Cord Blood Banks.....	25
2.2.1	Public Cord Blood Banks.....	25
2.2.1.1	WMDA Registry on Global Cord Blood Units.....	26
2.2.1.2	Public Cord Blood Banks in the U.S.....	28
2.2.1.3	Public Cord Blood Banks in Major European Countries.....	30
2.2.1.4	Economic Model of Public Cord Blood Banks.....	32
2.2.1.5	Cost Analysis for Public Cord Blood Banks.....	34
2.2.1.6	Relationship between Cost and Release Rates.....	34
2.2.2	Private Cord Blood Banks.....	35
2.2.2.1	Private Cord Blood Banks in the U.S.....	35
2.2.2.2	World's Top Ten Private Cord Blood Banks by Size of Inventory.....	37
2.2.2.3	Processing and Storage Charges in Private Cord Blood Banks, U.S.....	38
2.2.2.4	Processing & Storage Charges in Private Banks in Europe.....	39
2.2.2.5	Processing and Storage Fee Charged by LifeCell (India).....	40
2.2.2.6	Processing & Storage Fees Charged by Global Cord Blood Corp. (China) ..	40
2.2.2.7	Cost Analysis for Private Cord Blood Banks.....	41
2.2.2.8	Revenue Generation by Private Cord Blood Banks.....	42
2.2.2.9	Status and Noteworthy Features of Some U.S. Private Cord Blood Banks ..	43
2.2.2.10	Public vs. Private Cord Blood Banks.....	45
2.2.3	Hybrid Cord Blood Banks.....	46
2.2.3.1	Proportion of Public, Private and Hybrid Cord Blood Banks.....	47
2.2.4	Community Cord Blood Banks.....	48
2.3	Percent Share of Parents Storing Cord Blood by Country (Top 10).....	48
2.4	The Unique Benefits of Cord Blood Transplant.....	49
3.	CORD BLOOD BANK ACCREDITATIONS.....	51
3.1	Association for the Advancement Blood and Biotherapies (AABB).....	51
3.1.1	AABB Accreditation Phases and Expectations.....	52
3.2	Foundation for the Accreditation of Cellular Therapy (FACT).....	54
3.2.1	FACT Standards.....	55
3.2.3	FACT Accreditation Process.....	55
3.3	FDA-Registered Cord Blood Banks.....	56
3.4	FDA Biologics Application for Cord Blood.....	56
3.5	Investigation New Drug (IND) for Cord Blood.....	57
3.6	Human Tissue Authority (HTA).....	57
3.7	Therapeutic Goods Act (TGA).....	57
4.	PATENT LANDSCAPE OF CORD BLOOD, CORD TISSUE & PLACENTA.....	58
4.1	Patents on Umbilical Cord Blood Stem Cells.....	58
4.1.1	Legal Status of Cord Blood Stem Cell Patents.....	58
4.1.2	Umbilical Cord Blood Stem Cell Patent Applications by Year.....	60
4.1.3	Cord Blood Stem Cell Patent Applications by Jurisdiction.....	61
4.1.4	Umbilical Cord Blood Stem Cell Patent Applicants.....	63
4.1.5	Umbilical Cord Blood Stem Cell Inventors.....	66
4.1.6	Owners of Umbilical Cord Blood Stem Cell Patents.....	69

4.2	Patents of Umbilical Cord Tissue	72
4.2.1	Legal Status of Cord Tissue Patents	72
4.2.2	Umbilical Cord Tissue Patent Applications by Year	73
4.2.3	Umbilical Cord Tissue Patent Applications by Jurisdiction	75
4.2.4	Umbilical Cord Tissue Patent Applicants	77
4.2.5	Inventors of Umbilical Cord Tissue Patents	80
4.2.6	Owners of Umbilical Cord Tissue Patents	83
4.3	Patents on Placental Tissue.....	86
4.3.1	Placental Tissue Patent Applicants.....	87
4.3.2	Placental Tissue Patent Applications by Year	90
4.3.3	Placental Tissue Patents by Jurisdiction.....	91
4.3.4	Inventors of Placental Tissue Patents.....	93
4.3.5	Owners of Placental Tissue Patents	95
4.3.6	Legal Status of Placental Tissue Patents	98
4.4	Patents on Cord Blood Expansion	99
4.4.1	Number of Cord Blood Expansion Patent Applications by Year	100
4.4.2	Cord Blood Expansion Patent Applications by Jurisdiction	101
4.4.3	Legal Status of Cord Blood Expansion Patents	102
4.4.4	Inventors of Cord Blood Expansion Patents	103
4.4.5	Owners of Cord Blood Expansion Patents.....	106
5.	UMBILICAL CORD BLOOD RESEARCH PUBLICATIONS	110
5.1	Number of Papers Published on Umbilical Cord Blood (UCB)	110
5.2	Number of Papers Published in PubMed.gov on Umbilical Cord Tissue.....	112
5.3	Number of Papers Published on Placental Tissue.....	113
5.4	Published Papers on Cord Blood Expansion Methods	114
6.	CLINICAL TRIAL DATA	115
6.1	Clinical Trials Using Umbilical Cord Blood Units (CBUs).....	116
6.1.1	Number of Umbilical Cord Blood Clinical Trials by Study Type	116
6.1.2	Number of Cord Blood Clinical Trials by Phase of Study	117
6.1.3	Number of Cord Blood Clinical Trials by Funder Type	118
6.1.4	Diseases Addressed by Ongoing Cord Blood Clinical Trials	119
6.1.5	Companies Participating in Cord Blood Clinical Trials, April 18, 2025	120
6.2	Clinical Trials using Umbilical Cord Tissue	121
6.2.1	Umbilical Cord Tissue Clinical Trials by Phase of Study	122
6.2.2	Umbilical Cord Tissue Clinical Trials by Funder Type	123
6.2.3	Umbilical Cord Tissue Clinical Trials Sponsored by Companies	124
6.3	Placental Tissue Stem Cells in Clinical Trials	124
6.3.1	Placental Tissue Stem Cells in Clinical Trials by Phase of Study.....	125
6.4	Clinical Trials using Expanded Cord Blood	126
6.4.1	Major Participants in Expanded Cord Blood Clinical Trials.....	126
7.	CORD BLOOD PROCESSING TECHNOLOGIES	129
7.1	The Process of Separation of Cord Blood Stem Cells	129
7.1.1	Plasma Depletion (MaxCell Process)	131
7.1.2	Density Gradient	131
7.1.3	Hetastarch (HES)	132
7.1.4	PrepaCyte-CB	132
7.1.5	SEPAX	133
7.1.6	AutoXpress (AXP)	134
7.1.7	TotiCyte	134
7.1.8	MacoPress Smart.....	135
7.2	Performance Comparison of Cord Blood Processing Technologies.....	136
7.3	Days to Neutrophil Engraftment by Processing Technology	137
7.4	Anticoagulants used in Cord Blood Processing	138

7.5	Cryopreservation of Umbilical Cord Blood	139
7.6	Bioprocessing of Umbilical Cord Tissue.....	140
7.7	Cord Blood Expansion Technologies	140
7.7.1	Umbilical Cord Blood Expansion Strategies	141
7.7.1.1	Aryl Hydrocarbon Antagonists.....	141
7.7.1.2	Pyrimidoindole Derivatives	142
7.7.1.3	Nicotinamide.....	142
7.7.1.4	Notch Ligands	142
7.7.1.5	Copper Chelator	143
7.7.1.6	Valproic acid.....	143
8.	CORD BLOOD UNITS AVAILABLE WORLDWIDE: AN OVERVIEW	144
8.1	Number of Cord Blood Donors & CBUs Available Worldwide	146
8.2	CBUs Available by Geography.....	147
8.3	Cord Blood Units (CBUs) Registered in U.S. Registries.....	148
8.3.1	Cord Blood Units (CBUs) in the U.S. by Race and Ethnicity as of 2024	149
8.4	CBUs Available in Europe	150
8.5	CBUs Available in Asia/Pacific.....	151
8.6	HLA Typing of Unrelated Cord Blood Donors and CBUs Worldwide.....	152
8.6.1	Unrelated BM, PB and CB HSCs Shipped Worldwide	153
8.6.2	Global Exchange of Cord Blood Units (CBUs).....	155
8.7	WMDA's Search & Match Service.....	156
8.7.1	Number of Searches made in WMDA Registry for CBUs by Year	157
8.7.2	Yield of Search Results from WMDA Registry, 2017-2023	158
9.	INDICATIONS FOR UCB TRANSPLANTATION.....	159
9.1	Advantages of Cord Blood Stem Cells.....	160
9.1.1	Hematopoietic Properties of Cord Blood Stem Cells	160
9.1.2	Immune Properties of Cord Blood Stem Cells	160
9.1.3	Impact of HLA Mismatch in UCB Transplant Recipients	161
9.2	Malignant Indications Addressable by UCB Transplantation	161
9.3	Non-Malignant Indications for CBU Transplantation	163
9.4	Application of UCB in Regenerative Medicine	164
10.	CORD BLOOD: A TRANSPLANT MEDICINE	165
10.1	Worldwide PB, BM & CB Transplants Compared	165
10.2	Cord Blood Stem Cells Transplantation by Geography	166
10.2.1	CBU Transplantations in Asia	167
10.2.2	UCB Transplants in North America	168
10.2.3	UCB Transplants in Europe	169
10.2.4	UCB Transplants in Oceania.....	170
10.2.5	CBU Transplants in South America	171
10.3	Cost of UCB Transplantation	172
10.3.1	Complications through 1-Year Post HSCT	173
11.	CORD BLOOD STEM CELLS IN REGENERATIVE MEDICINE	175
11.1	Autism	175
11.2	Cerebral palsy	176
11.3	Alzheimer's Disease.....	177
11.4	Diabetes	178
11.5	Heart Diseases.....	179
11.6	Multiple Sclerosis	179
11.7	Stroke	180
12.	MARKET ANALYSIS	181
12.1	Umbilical Cord Blood Banking Services Market.....	181

12.1.1	Umbilical Cord Blood (UCB) Banking Market Share by Geography, 2024 ..	183
12.1.2	Public vs. Private Cord Blood Banking Service Market	184
12.1.3	Global Market Share for Cord Blood & Cord Tissue Banking Services	185
12.1.4	Market Share of CB for Transplantation & Regenerative Medicine	186
12.1.5	Percent Share of Cord Blood & Cord Tissue Market by Indication	187
12.2	Global Market for Umbilical Cord Tissue Banking Service	188
12.3	Historical Revenue Analysis of the Cord Blood Industry.....	190
12.4	Geographical Revenue Variations in Cord Blood Banking	191
12.5	Innovations Impacting Cord Blood Banking Revenue.....	192
12.6	Growth Drivers for the Cord Blood Industry	193
13.	PROFILES OF SELECT CORD BLOOD BANKS & RELATED ORGANIZATIONS	195
13.1	AllCells	195
13.1.1	Research Use Only (RUO) Products	195
13.1.1.1	Mobilized Leukopak	196
13.1.1.2	Leukopak	196
13.1.1.3	Bone Marrow.....	196
13.1.1.4	Cord Blood	196
13.1.1.5	Whole Blood.....	197
13.1.2	GMP Products	197
13.1.2.1	Clinical Grade Mobilized Leukopak	197
13.1.2.2	Clinical Grade Leukopak.....	197
13.1.2.3	Clinical Grade Bone Marrow.....	198
13.1.3	Isolated Cell Products	198
13.1.3.1	CD34+ HSPCs	198
13.1.3.2	T Cells	198
13.1.3.3	NK Cells	199
13.1.3.4	Monocytes.....	199
13.1.3.5	B Cells.....	199
13.1.3.6	PBMCs (MNCs)	199
13.2	AlphaCord	200
13.2.1	Prices	200
13.3	Americord Registry, Inc.....	201
13.4	Angiocrine Bioscience	201
13.4.1	Proprietary E-CEL Platform.....	202
13.5	Anja Health Personalized Cord Blood Banking.....	202
13.5.1	Anja's Manual Processing of Cord Blood.....	203
13.6	Anthony Nolan.....	203
13.6.1	Products & Services.....	204
13.6.1.1	Cell Isolation & Purification	204
13.6.1.2	Cell Culture & Expansion	204
13.7	Baylx, Inc.....	204
13.7.1	Core Technology	205
13.7.2	Product Pipeline	205
13.8	NMDP SM	206
13.8.1	NMDP Network.....	206
13.9	Biocell Center	207
13.10	BioEden.....	208
13.10.1	Dental Pulp Cells.....	208
13.10.2	Differences between Dental Pulp Cells and Cord Blood Cells	208
13.11	BiolIntegrate, LLC	209
13.11.1	GeneXSTEM Injectables.....	209
13.12	Bloodworks Northwest	210
13.12.1	Products & Services	210
13.13	California Umbilical Cord Collection Program.....	211
13.13.1	Participating Locations	211

13.14	Carolinas Cord Blood Bank (CCBB)	212
13.15	Celaid Therapeutics	213
13.15.1	<i>In Vitro</i> Expansion Technology	213
13.15.2	Business Model	213
13.16	Celebration Stem Cell Centre (CSCC)	214
13.16.1	Products	214
13.17	Cell Care	215
13.18	Cellenkos, Inc.	216
13.18.1	Technology	216
13.18.2	Cellenkos' Pipeline	216
13.19	Cells4Life Group LLP	218
13.19.1	<i>Cellsplus</i>	218
13.19.2	TotiCyte Processing Technology	218
13.19.3	Cord Blood Releases from Cells4Life	219
13.20	CellSave Arabia	220
13.20.1	Cord Blood Stem Cell Banking Services	220
13.20.2	Stem Cell Banking Price	220
13.21	Celularity, Inc.	221
13.22	Center for International Blood and Marrow Transplant Research (CIBMTR)	222
13.23	CHOC Blood Bank	225
13.24	Cleveland Cord Blood Center	226
13.24.1	Research on Diabetic Retinopathy	226
13.24.2	Research on Type I Diabetes	226
13.24.3	Research on Parkinson's disease	227
13.24.4	Research on Wound Healing	227
13.25	ClinImmune Cell and Gene Therapy	228
13.25.1	FDA Licensed Cord Blood	228
13.25.2	Gene Therapy	228
13.25.3	Cellular Therapies	229
13.26	Cord Blood Bank of Arkansas (CBBA)	229
13.27	Cord Blood Center Group	229
13.28	Cord Blood Registry (CBR)	230
13.28.1	Business Experience	230
13.28.2	Licensing & Accreditation	230
13.28.3	Pricing	231
13.29	Cord for Life	231
13.29.1	Technology: PremierMax	231
13.30	CordLife Group, Ltd.	232
13.30.1	Accreditations & Certifications	232
13.30.2	Services	232
13.30.3	Cordlife Group's Network	233
13.30.4	Cordlife's Market	233
13.31	CordVida	235
13.32	Crioestaminal	236
13.32.1	Cord Blood Transplantation in Portugal	236
13.33	Cryo-Cell International, Inc.	237
13.33.1	Processing Technology	237
13.33.2	Recovery of Viable CFU by PrepaCyte-CB	237
13.33.3	Cryo-Cell International's Revenue Generation	238
13.33.4	Cryo-Cell International's Pricing	239
13.34	CryoCyte, LLC	240
13.35	CryoHoldco LATAM	241
13.36	Cryopoint	242
13.37	Cryoviva Biotech Pvt., Ltd.	242
13.38	DKMS gGMBH	243
13.38.1	Cord Blood Units	243

13.38.2	Services	243
13.38.3	DKMS' Donor Typing Profile & Active Donors	244
13.39	Duke University School of Medicine	245
13.39.1	Ducord (HPC Cord Blood)	245
13.40	European Society for Blood and Bone Marrow Transplantation (EBMT)	246
13.40.1	EBMT Transplant Activity	246
13.41	Ever Supreme Bio Technology, Co., Ltd.	247
13.41.1	Allogeneic UMSC01	247
13.41.2	New Research	248
13.42	ExCellThera	248
13.42.1	ECT-001 Cell Therapy	249
13.43	FamiCord Group	249
13.44	Fate Therapeutics, Inc.	250
13.44.1	FT1050 – Stem Cell Modulator	250
13.45	Future Health	251
13.45.1	Locations of Laboratories	251
13.45.2	Business Experience	252
13.45.3	Collection Kit	252
13.45.4	Transportation Container	252
13.45.5	Processing Method	252
13.45.6	Components Stored	253
13.45.7	Storage Methods	253
13.45.8	Licensing & Accreditation	253
13.45.9	Prices	253
13.45.10	Additional Services	254
13.46	Gamida Cell	254
13.46.1	OMIDUBICELL	254
13.47	GeneCell	255
13.48	Global Cord Blood Corporation (GCBC)	256
13.48.1	GCBC's Revenue Generation	256
13.49	Glycostem Therapeutics	258
13.49.1	Science and Technology	258
13.49.2	oNKord	258
13.49.3	viveNK	259
13.49.4	uNiK Production Process	259
13.50	Hawaii Cord Blood Bank	260
13.51	HealthBaby	261
13.51.1	Service Plans	261
13.51.2	18-Year Cord Blood (HSCs) Storage Plan	261
13.51.3	18-Year CordBasic Umbilical Cord Lining Storage Plan	262
13.51.4	CellOptima CordPlus Umbilical Cord Lining Storage	262
13.52	HealthBanksUSA	263
13.52.1	BioArchive Cryogenic Storage System	263
13.52.2	AXP Cord Blood Processing	263
13.53	HEMAFUND	264
13.54	Hemogenyx Pharmaceuticals	265
13.54.1	Technology	265
13.55	IMMUNIQUE	266
13.56	Inseption LifeBank	267
13.56.1	Cord Blood Releases from Inseption LifeBank	267
13.56.2	Cord Blood Cells Released for Regenerative Medicine from Inseption	269
13.57	JP McCarthy Cord Stem Cell Bank	273
13.58	Kangstem Biotech, Co., Ltd.	274
13.58.1	GD11 Brand	274
13.58.2	Core Technology	274
13.59	LifebankUSA	275

13.60	LifeCell International Pvt. Ltd.	276
13.61	Life Line Stem Cell	277
13.62	LifeSouth Cord Blood Bank	279
13.62.1	Accreditation & Hospital Partners	279
13.63	Magenta Therapeutics	281
13.63.1	Magenta's Cord Blood-Based Clinical Trial	281
13.64	Maze Cord Blood	282
13.65	Medipost, Co., Ltd.	283
13.65.1	Medipost's Product & Products in Development	283
13.65.1.1	CARTISTEM	283
13.65.1.2	PNEUMOSTEM	283
13.65.1.3	SMUP-IA-01	284
13.66	MD Anderson Cord Blood Bank	284
13.67	Mesoblast, Ltd.	285
13.67.1	Mesoblast's UCB-Based Clinical Trial	285
13.68	MiracleCord, Inc.	286
13.68.1	AXP II Automated Processing	286
13.68.2	StemCare Collection Kit	286
13.68.3	Cost of Cord Blood Banking	286
13.69	Mononuclear Therapeutics, Ltd.	288
13.69.1	MonoTx Cord Blood Bank	288
13.69.2	MonoTx's Pipeline	288
13.69.3	Products	289
13.69.3.1	Human Cord Blood Mononuclear Cells (MNCs)	289
13.69.3.2	Exosome Rich Plasma (ERP)	289
13.69.3.3	Activated Human Cord Blood Platelet-Depleted-Plasma (aPDP)	290
13.70	New England Cord Blood Bank, Inc.	291
13.70.1	Cord Blood Processing	291
13.70.2	Cord Blood & Tissue Storage	291
13.71	New York Blood Center	292
13.71.1	Blood Products & Services	292
13.71.2	Cell Therapies	293
13.71.3	Cord Blood	293
13.72	OrganaBio	294
13.72.1	OrganaBio's Proprietary Supply Chains	294
13.72.2	Perenatal Tissues	294
13.73	PacifiCord	295
13.73.1	FDA-Approved Sterile Collection Bags	295
13.73.2	AXP Processing System	295
13.73.3	BioArchive System	295
13.74	Plasticell Ltd.	296
13.74.1	CombiCult Technology	296
13.74.2	Hematopoietic Stem Cell Expansion	296
13.75	ReeLabs Pvt. Ltd.	297
13.76	Restem, LLC	298
13.76.1	Clinical Trial for COVID-19	298
13.76.2	Clinical Trial for Muscular Dystrophy	299
13.76.3	Clinical Trial for Idiopathic Inflammatory Myositis (IIM)	299
13.76.4	Clinical Trial for Heart Failure	299
13.77	San Diego Cord Blood Bank	300
13.78	Saneron CCEL Therapeutics, Inc.	301
13.78.1	U-CORD-CELL Program	301
13.78.2	SERT-CELL Program	301
13.79	SmartCells	302
13.80	SSM Cardinal Glennon Children's Medical Center	303
13.80.1	ALLOCORD	303

13.81	Stembanc, Inc.	304
13.81.1	Popular Packages from Stembanc	304
13.82	Stem Cell Cryobank, Inc.	305
13.83	StemCyte, Inc.	306
13.83.1	Services	306
13.83.2	Add On Services	307
13.83.3	StemCyte in Clinical Trials	307
13.83.4	StemCyte's Plans & Pricing	307
13.84	Throne Biotechnologies, Inc.	308
13.84.1	Effects of CB-SCs in Diabetics	308
13.84.2	Effects of CB-SCs on Alopecia Areata	308
13.85	Transcell Biolife	309
13.85.1	ScellCare	309
13.85.2	ToothScell	309
13.86	Upstate Cord Blood Bank	310
13.87	ViaCord	311
13.87.1	ViaCord's Complete Services	311
13.87.2	Cord Blood + Tissue Banking	311
13.87.3	Newborn Digestive Health	311
13.87.4	Newborn DNA Guardian	312
13.88	Versity, Inc.	312
13.89	Vita 34 AG (Recently Merged with Famicord)	313
13.89.1	Revenue Generation by Vita 34 AG	313
13.90	Vitalant Clinical Services	315
13.90.1	Hospital Services	315
13.90.2	Laboratory Services	315
13.90.3	Research	316
13.91	World Marrow Donor Association (WMDA)	317
13.91.1	WMDA Search & Match Service	317
13.92	Worldwide Network for Blood & Marrow Transplantation (WBMT)	318

APPENDIX

APPENDIX 1: Advancements in Umbilical Cord Blood Banking	319
Appendix 1.1: Market Growth and Trnds	320
Appendix 1.2: Advances in Automation and Cryopreservation	320
Appendix 1.3: Advances in Isolation Methods	322
Appendix 1.4: Expanding Applications of CBUs	323
Appendix 1.5: Potential of Artificial Intelligence (AI) in UCB Banking	323

INDEX OF FIGURES

FIGURE 2.1: Schematic Cross-Sectional View of Umbilical Cord	22
FIGURE 2.2: Percent Utilization of HSCs by Type in Pediatric Patients	23
FIGURE 2.3: Composition of a Cord Blood Sample	24
FIGURE 2.4: World's Top Ten Private Cord Blood Banks by Inventory Size	38
FIGURE 2.5: Revenue Generation in Three Major Private Cord Blood Banks, 2017-2024	43
FIGURE 2.6: Proportion of Public, Private and Hybrid Cord Blood Banks	47
FIGURE 2.7: Percent Share of Parents Storing Cord Blood in Top Ten Countries	49
FIGURE 4.1: Legal Status of Umbilical Cord Blood Stem Cell Patents	59

FIGURE 4.2: Number of Applications for Umbilical Cord Blood Stem Cells, 2000-2024 61

FIGURE 4.3: Legal Status of Cord Tissue Patents 73

FIGURE 4.4: Umbilical Cord Tissue Patent Applications, 2000-2024..... 75

FIGURE 4.5: Placental Tissue..... 75

FIGURE 4.6: Placental Tissue Patent Applications by Year 91

FIGURE 4.7: Cord Blood Expansion Patent Applications by Year..... 101

FIGURE 5.1: Number of Papers on Umbilical Cord Blood in PubMed.gov, 2000-2024 111

FIGURE 5.2: Number of Papers Published in PubMed.gov on Cord Tissue, 2000-2024..... 112

FIGURE 5.3: Number of Published Papers on Placental Tissue, 2000-2024 113

FIGURE 5.4: Published Papers on Cord Blood Expansion in PubMed.gov..... 114

FIGURE 6.1: Percent Share of UCB Clinical Trials by Study Type, April 18, 2025 117

FIGURE 6.2: Percent Share of Cord Blood Clinical Trials by Phase of Study, April 18, 2025 ... 118

FIGURE 6.3: Percent Share of Cord Blood Clinical Trials by Funder Type, April 18, 2025..... 119

FIGURE 6.4: Percent Share of Studies Addressing Various Diseases, April 18, 2025 120

FIGURE 6.5: Umbilical Cord Tissue Clinical Trials by Phase of Study, April 19, 2025..... 122

FIGURE 6.6: Umbilical Cord Tissue Clinical Trials, April 19, 2025 123

FIGURE 6.7: Placental Stem Cells in Clinical Trials by Phase of Study, April 19, 2025..... 125

FIGURE 7.1: The Buffy Coat of Cord Blood after Centrifugation 130

FIGURE 7.2: Cord Blood Sample Bag after Plasma Depletion 131

FIGURE 7.4: PrepaCyte-CB System..... 133

FIGURE 7.5: SEPAX 133

FIGURE 7.6: AutoXpress 134

FIGURE 7.7: TotiCyte Processing Steps 135

FIGURE 7.9: Percent Viable Stem Cells in the Processed Cord Blood by Technology 136

FIGURE 7.10: Days to Neutrophil Engraftment by Technology 137

FIGURE 7.11: Stem Cell (CD34+) and Nucleated White Cell Count with CPD and Heparin 138

FIGURE 7.12: A Comparative Analysis with Three Different Cryoprotectants 139

FIGURE 8.1: Number of CB Donors and CBUs available Worldwide, 1997-2024 147

FIGURE 8.2: Cord Blood Units (CBUs) Registered in the U.S. Registries by Year, 2001-2024. 150

FIGURE 8.3: HLA Typing of Unrelated Cord Blood Donors and CBUs Worldwide 153

FIGURE 8.4: HSCs of BM, PB and CB Shipped Worldwide, 1997-2023..... 155

FIGURE 8.5: Global Exchange of CBUs, 2023 156

FIGURE 8.6: Number of Searches made in WMDA Registry for CBUs, 2017-2023 157

FIGURE 8.7: Yield of Search Results from WMDA Registry, 2017-2023 158

FIGURE 9.1: Percent Utilization of PB, BM and CB Worldwide, 1997-2023 159

FIGURE 10.1: Worldwide PB, BM & CB Transplants Compared..... 166

FIGURE 10.2: CBU Transplantations in Asia, 1999-2003 168

FIGURE 10.3: UCB Transplants in North America..... 169

FIGURE 10.4: CUB Transplants in Europe 170

FIGURE 10.5: UCB Transplants in Oceania 171

FIGURE 12.1: Global Cord Blood Banking Service Market, 2024-2032 183

FIGURE 12.2: Percent Share of Cord Blood Service Market by Geography, 2024 184

FIGURE 12.3: Public vs. Private Cord Blood Banking Service Market 185

FIGURE 12.4: Global Market Share for Cord Blood & Cord Tissue Banking Services, 2024..... 186

FIGURE 12.5: Market Share of CB for Transplantation & Regenerative Medicine..... 187

FIGURE 12.6: Percent Share of Cord Blood & Cord Tissue Market by Indication 188

FIGURE 13.1: Funders for CIBMTR in 2023..... 222

FIGURE 13.2: Sales Revenues and Gross Profits for CordLife, 2014-2023 234

FIGURE 13.3: Cryo-Cell International’s Revenue Generation, 2017-2023.....	238
FIGURE 13.4: GCBC’s Revenue Generation, 2015-2022	257
FIGURE 13.5: Revenue Generation by Vita 34 AG, 2014-2021	314
FIGURE App.1.1: Proportion of Clinical Conditions Investigated using UCB-MSCs	323

INDEX OF TABLES

TABLE 2.1: General Features of Public Cord Blood Banks	26
TABLE 2.2: Number of CBUs in WMDA Registry	27
TABLE 2.2: (CONTINUED)	28
TABLE 2.3: Public Cord Blood Banks in the U.S.	29
TABLE 2.4: Public Cord Blood Banks in European Countries	30
TABLE 2.4: (CONTINUED)	31
TABLE 2.4: (CONTINUED)	32
TABLE 2.5: International Prices of Cord Blood Unit (CBU).....	32
TABLE 2.6: Prices of CBUs in NMDP Banks in the U.S.	33
TABLE 2.7: General Features of Private Cord Blood Banks.....	35
TABLE 2.8: Leading Private Cord Blood Banks in the U.S.	36
TABLE 2.9: World’s Top Ten Private Cord Blood Banks by Inventory Size.....	37
TABLE 2.10: Processing and Storage Charges in CBR (U.S.)	39
TABLE 2.11: Processing and Storage Fee Charged by Vita34 (Europe)	39
TABLE 2.12: Processing and Storage Fees Charged by LifeCell (India).....	40
TABLE 2.13: Processing & Storage Fees Charged by Global Cord Blood Corp. (China)	41
TABLE 2.14: Revenue Generation by Three Major Private Cord Blood Banks, 2017-2024	42
TABLE 2.15: Examples of Hybrid Cord Blood Banks	47
TABLE 2.16: Percent Share of Parents Storing Cord Blood in Top Ten Countries	48
TABLE 3.1: AABB Accredited Cord Blood Banks	52
TABLE 3.1: (CONTINUED)	53
TABLE 3.1: (CONTINUED)	54
TABLE 3.2: Select FACT-Accredited Cord Blood Banks	55
TABLE 4.1: Legal Status of Umbilical Cord Stem Cell Patents.....	59
TABLE 4.2: Umbilical Cord Blood Stem Cell Patent Applications by Year	60
TABLE 4.3: Umbilical Cord Blood Patent Applications by Jurisdiction.....	62
TABLE 4.4: Applicants of Umbilical Cord Patents	63
TABLE 4.4: (CONTINUED)	64
TABLE 4.4: (CONTINUED)	65
TABLE 4.5: Umbilical Cord Blood Stem Cell Patent Inventors	66
TABLE 4.5 (CONTINUED)	67
TABLE 4.5: (CONTINUED)	68
TABLE 4.6: Owners of Umbilical Cord Blood Stem Cell Patents	69
TABLE 4.6: (CONTINUED)	70
TABLE 4.6: (CONTINUED)	71
TABLE 4.6: (CONTINUED)	72
TABLE 4.7: Legal Status of Cord Tissue Patents	73
TABLE 4.8: Number of Umbilical Cord Tissue Patent Applications, 2000-2024	74
TABLE 4.9: Umbilical Cord Tissue Patent Applications by Jurisdiction	76
TABLE 4.10: Umbilical Cord Tissue Patent Applicants	77
TABLE 4.10: (CONTINUED)	78
TABLE 4.10: (CONTINUED)	79
TABLE 4.11: Umbilical Cord Tissue Patent Inventors	80

TABLE 4.11: (CONTINUED)	81
TABLE 4.11: (CONTINUED)	82
TABLE 4.12: Owners of Umbilical Cord Tissue Patents	83
TABLE 4.12: (CONTINUED)	84
TABLE 4.12: (CONTINUED)	85
TABLE 4.13: Placental Tissue Patent Applicants.....	87
TABLE 4.13: (CONTINUED)	88
TABLE 4.13: (CONTINUED)	89
TABLE 4.14: Placental Tissue Patent Applications by Year	90
TABLE 4.15: Placental Tissue Patent Jurisdictions	92
TABLE 4.16: Inventors of Placental Tissue Patents.....	93
TABLE 4.16: (CONTINUED)	94
TABLE 4.16: (CONTINUED)	95
TABLE 4.17: Owners of Placental Tissue Patents	96
TABLE 4.17: (CONTINUED)	97
TABLE 4.17: (CONTINUED)	98
TABLE 4.18: Legal Status of Placental Tissue Patents	99
TABLE 4.19: Cord Blood Expansion Patent Applications by Year.....	100
TABLE 4.20: Cord Blood Expansion Patent Applications by Jurisdiction	101
TABLE 4.20: (CONTINUED)	102
TABLE 4.21: Legal Status of Cord Blood Expansion Patents	103
TABLE 4.22: Inventors of Cord Blood Expansion Patents	103
TABLE 4.22: (CONTINUED)	104
TABLE 4.22: (CONTINUED)	105
TABLE 4.22: (CONTINUED)	106
TABLE 4.23: Owners of the Cord Blood Expansion Patents	106
TABLE 4.23: (CONTINUED)	107
TABLE 4.23: (CONTINUED)	108
TABLE 4.23: (CONTINUED)	109
TABLE 6.1: Total Number of Clinical Trials (CBU, CT, PT and Expanded CBU), Apr. 2025.....	115
TABLE 6.2: Number of Umbilical Cord Blood Clinical Trials by Study Type, April 18, 2025.....	116
TABLE 6.3: Number of Cord Blood Clinical Trials by Phase of Study, April 18, 2025	117
TABLE 6.4: Number of Cord Blood Clinical Trials by Funder Type, April 18, 2025	118
TABLE 6.5: Select Companies Sponsoring Cord Blood Clinical Trials	120
TABLE 6.5: (CONTINUED)	121
TABLE 6.6: Umbilical Cord Tissue Clinical Trials by Phase of Study, April 19, 2025	122
TABLE 6.7: Umbilical Cord Tissue Clinical Trials by Funder Type, April 19, 2025	123
TABLE 6.8: Select Companies Sponsoring Cord Tissue Clinical Trials, April 19, 2025	124
TABLE 6.9: Placental Tissue Stem Cells in Clinical Trials by Phase of Study, April 19, 2025 ...	125
TABLE 6.10: Major Clinical Trials Using Expanded Umbilical Cord Blood Cells	127
TABLE 6.10: (CONTINUED)	128
TABLE 7.1: Umbilical Cord Blood Expansion Strategies	141
TABLE 8.1: Umbilical Cord Blood Units Registered with WMDA, April 22, 2025	144
TABLE 8.1: (CONTINUED)	145
TABLE 8.2: Number of CB Donors and CBU's available Worldwide, 1997-2024.....	146
TABLE 8.3: Number of Cord Blood Donors and CBU's available by Geography, 2023	148
TABLE 8.4: Available CBU's in the U.S. by Race & Ethnicity, September 30, 2024	150
TABLE 8.5: CBU's Available in Europe as of April 23, 2025	150
TABLE 8.5: (CONTINUED)	151
TABLE 8.6: CBU's Available in Asia/Pacific as of April 23, 2025	151
TABLE 8.7: HSCs of BM, PB and CB Shipped Worldwide, 1997-2023	154
TABLE 8.8: Number of Searches made in WMDA Registry for CBU's, 2017-2023	157
TABLE 8.9: Yield of Search Results from WMDA Registry, 2017-2023	158

TABLE 9.1: Malignant Indications Addressed by UCB Transplantation.....	162
TABLE 9.2: Non-Malignant Indications for CUB Transplantation.....	163
TABLE 9.3: Diseases Targeted by Cord Blood Cells as Regenerative Medicines	164
TABLE 10.1: Worldwide PB, BM & CB Transplants Compared	165
TABLE 10.2: CBU Transplantations by Geography, 1999-2023.....	167
TABLE 10.3: Comparison of Median Cost during Admit for CB, PB and BM HSCTs	173
TABLE 10.4: Complications through 1-Year Post HSCT	174
TABLE 11.1: UCB & UCBT in Clinical Trials on Autism	176
TABLE 11.2: A Sample List of Clinical Trials for Cerebral Palsy using CBUs	177
TABLE 11.3: A Sample List of Clinical Studies for Alzheimer’s Disease using CBUs	177
TABLE 11.4: A Sample List of Clinical Studies for Diabetes using CBUs	178
TABLE 11.5: A Small List of Clinical Studies for Heart Diseases using CBUs	179
TABLE 11.6: A Short List of Clinical Studies for Multiple Sclerosis using CBUs	180
TABLE 12.1: Global Cord Blood Banking Service Market, 2024-2032	182
TABLE 12.2: Global Market for Cord Tissue Banking Service, 2024-2032.....	189
TABLE 13.1: Angiocrine’s R&D Pipeline	202
TABLE 13.2: Baylx’s hUC-MS-Derived Product Pipeline	205
TABLE 13.3: NMDP Network of Cord Blood Banks	206
TABLE 13.3: (CONTINUED)	207
TABLE 13.4: Cell Care’s Pricing for Cord Blood Processing and Storage.....	215
TABLE 13.5: Cellenkos’ Product Pipeline	217
TABLE 13.6: Cord Blood Releases from Cells4Life	219
TABLE 13.7: Celularity’s Active Clinical Pipeline	221
TABLE 13.8: Recovery of Viable CFU by PrepaCyte-CB	237
TABLE 13.9: Cryo-Cell International’s Revenue Generation, 2017-2023	238
TABLE 13.10: Cryo-Cell International’s Pricing.....	242
TABLE 13.11: CryoCyte’s Option Plans & Pricing	240
TABLE 13.12: DKMS’ Donor Typing Profile & Active Donors	244
TABLE 13.13: EBMT Transplant Activity, 2023.....	247
TABLE 13.14: Cord Blood Banking Cost in GeneCell.....	255
TABLE 13.15: GCBC’s Revenue Generation, 2015-2022.....	256
TABLE 13.16: Glycostem’s Product Pipeline	259
TABLE 13.17: Inseption LifeBank’s Pricing	267
TABLE 13.18: Cord Blood Releases from Inseption LifeBank for Transplantation	268
TABLE 13.18: (CONTINUED)	269
TABLE 13.19: Cord Blood Cells Released for Regenerative Medicine from Inseption.....	270
TABLE 13.19: (CONTINUED)	271
TABLE 13.19: (CONTINUED)	272
TABLE 13.20: Kangstem’s Sponsor Initiated Clinical Trials.....	274
TABLE 13.21: LifeCell International’s Pricing.....	276
TABLE 13.22: Maze Cord Blood: Banking Cost.....	282
TABLE 13.23: MiracleCord’s Cord Blood Banking Cost	287
TABLE 13.24: MonoTx’s Product Pipeline	289

About BioInformant:

Founded in 2006, BioInformant is the world's first and only market research firm to specialize in the stem cell industry. Headquartered near Washington, DC, to be situated near the U.S. FDA, NIH, and Capitol Hill, BioInformant has collected 19+ years of historical data on the stem cell industry, providing a robust and unusual foundation on which to base its market research.

BioInformant operates the world's largest stem cell industry news site, attracting nearly a million readers per year. BioInformant research has been cited by the Wall Street Journal and quoted by Tony Robbins in his best-selling book, Life Force.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.

